FDA Expands Pediatric Suicidality Caution To Antidepressants Beyond Paxil
Executive Summary
FDA is expanding its concerns about the suicide potential of antidepressants in pediatric patients beyond GlaxoSmithKline's Paxil
You may also be interested in...
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
GSK Faces New York Suit Over Paxil: Publish Or Punish?
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
FDA Requests Antidepressant Labeling Add Suicidality Warning
FDA is requesting that labeling for 10 antidepressants include a warning recommending close monitoring of adult and pediatric patients for suicidal behavior